Exelixis | EXEL - Gross Profit On Sales


Exelixis reported $572.18M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Agios Pharmaceuticals USD 18.09M 6.89M Dec/2025
Akebia Therapeutics USD 49.21M 13.25M Mar/2025
Amgen USD 6.48B 307M Sep/2025
AstraZeneca USD 12.39B 5M Dec/2025
Bayer EUR 5.35B 1.02B Sep/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Cytokinetics USD 17.76M 15.82M Dec/2025
Eisai JPY 168.85B 17.02B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
Exelixis USD 572.18M 7M Dec/2025
Genmab DKK 868M 195M Jun/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Incyte USD 1.39B 118.68M Dec/2025
Ionis Pharmaceuticals USD 195M 40M Dec/2025
MacroGenics USD 61.25M 88.71M Sep/2025
Merck USD 13.42B 431M Sep/2025
Moderna USD 226M 583M Dec/2025
Nektar Therapeutics USD 13.75M 650K Jun/2024
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Novartis USD 10.82B 695M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sanofi EUR 8.45B 3.02B Dec/2025
Takeda JPY 790.55B 262.97B Dec/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Xencor USD 21M 22.61M Sep/2025